Flow Cytometry Improved Updated Spectral Analyzer
|
By LabMedica International staff writers Posted on 31 Oct 2019 |

Image: The Aurora advanced flow cytometry system is now available with five lasers to enable seeing more than 30 colors from a single sample (Photo courtesy of Cytek Biosciences).
Flow cytometry aims to count the number, size, granularity, and other properties of cells in a heterogeneous population. Standard flow cytometry lasers excite certain fluorescent markers (fluorochromes, antibodies, or stains) on a cell as it passes through the beam.
Detectors in the instrument record and quantify the relative amount of light emitted by fluorescent markers in the cell, which the tool presents to scientists through a histogram. However, flow cytometer users can run into a myriad of technical issues, such as dealing with limited sample volumes and lacking enough lasers to excite a target amount of fluorochromes. Each laser also can only excite a certain number of fluorochromes on a cell before inducing spectral overlap.
An updated model of its Aurora flow cytometry system has been released by Cytek Biosciences (Fremont, CA, USA), which offers scientists the ability to multiplex 40 fluorescent biomarkers on a cell in a blood sample for scientific and clinical purposes. The updated Aurora platform uses five optical lasers (ultraviolet, violet, blue, yellow-green, and red) to excite 40 fluorochromes on cellular antibodies, which are then recorded by 64 detectors.
With standard flow cytometry panels, a patient's blood sample must be separated into multiple tubes to identify biomarkers linked to different types of leukemia; however the Aurora platform only needs a single tube of blood to identify the fluorescent antibodies. While scientists still need to run controls prior to running a multicolor tube to measure the different emission spectra recorded by Aurora, they can save the controls in the software and reuse them with the same panel in future tests.
Wenbin Jiang, PhD, CEO of Cytek Biosciences, said, “After chemotherapy, no one really has that many bone marrow samples available for testing and splitting into several different tubes. But because you don't need to split blood samples into several tubes with Aurora, you can have more cells per tube, which leads to more specific results." Dr. Jiang also argued that the updated Aurora system can analyze up to 30,000 to 40,000 cells per second while maintaining a "competitive sensitivity." Flow cytometry platforms on the market currently offer anywhere from 20,000 to 100,000 cells per second, but not always at the sample level of multiplexing.
Steven A. Porcelli, MD, scientific director at the Albert Einstein College of Medicine Flow Cytometry Core (Bronx, NY, USA), said, “Cytek's tool collected light coming out over a wide range of wavelengths for each cell and for each laser that we've used to excite the cell. Instead of giving you a high or low value for a tracer, it allows you to distinguish many different tracers from each other because you create a kind of fingerprint of the wavelengths being emitted.”
Related Links:
Cytek Biosciences
Albert Einstein College of Medicine Flow Cytometry Core
Detectors in the instrument record and quantify the relative amount of light emitted by fluorescent markers in the cell, which the tool presents to scientists through a histogram. However, flow cytometer users can run into a myriad of technical issues, such as dealing with limited sample volumes and lacking enough lasers to excite a target amount of fluorochromes. Each laser also can only excite a certain number of fluorochromes on a cell before inducing spectral overlap.
An updated model of its Aurora flow cytometry system has been released by Cytek Biosciences (Fremont, CA, USA), which offers scientists the ability to multiplex 40 fluorescent biomarkers on a cell in a blood sample for scientific and clinical purposes. The updated Aurora platform uses five optical lasers (ultraviolet, violet, blue, yellow-green, and red) to excite 40 fluorochromes on cellular antibodies, which are then recorded by 64 detectors.
With standard flow cytometry panels, a patient's blood sample must be separated into multiple tubes to identify biomarkers linked to different types of leukemia; however the Aurora platform only needs a single tube of blood to identify the fluorescent antibodies. While scientists still need to run controls prior to running a multicolor tube to measure the different emission spectra recorded by Aurora, they can save the controls in the software and reuse them with the same panel in future tests.
Wenbin Jiang, PhD, CEO of Cytek Biosciences, said, “After chemotherapy, no one really has that many bone marrow samples available for testing and splitting into several different tubes. But because you don't need to split blood samples into several tubes with Aurora, you can have more cells per tube, which leads to more specific results." Dr. Jiang also argued that the updated Aurora system can analyze up to 30,000 to 40,000 cells per second while maintaining a "competitive sensitivity." Flow cytometry platforms on the market currently offer anywhere from 20,000 to 100,000 cells per second, but not always at the sample level of multiplexing.
Steven A. Porcelli, MD, scientific director at the Albert Einstein College of Medicine Flow Cytometry Core (Bronx, NY, USA), said, “Cytek's tool collected light coming out over a wide range of wavelengths for each cell and for each laser that we've used to excite the cell. Instead of giving you a high or low value for a tracer, it allows you to distinguish many different tracers from each other because you create a kind of fingerprint of the wavelengths being emitted.”
Related Links:
Cytek Biosciences
Albert Einstein College of Medicine Flow Cytometry Core
Latest Technology News
- Training Device Improves Accuracy of Pooled Molecular Diagnostics
- New CE-Certified Software Advances Whole-Genome Cancer Testing
- National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
- AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
- Agentic AI Platform Supports Genomic Decision-Making in Oncology
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
- Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
- AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
- Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Channels
Clinical Chemistry
view channel
Common HbA1c Assay May Miss Diabetes in People with Sickle Cell Trait
Accurate diabetes detection is essential because early identification guides timely management, yet test performance can vary in people with hemoglobin variants such as sickle cell trait.... Read more
Blood Protein Panel Predicts Timing of ALS Symptom Onset
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease in which clinical signs often emerge only after substantial motor neuron injury has already occurred, complicating timely intervention.... Read moreMolecular Diagnostics
view channel
AI Tool Improves Long-Read Detection of Cancer Mutations
Accurate identification of somatic mutations remains difficult, particularly in structurally complex genomic regions. Short-read sequencing pipelines can miss clinically relevant variants, limiting research... Read more
FDA Clears Molecular Test for Bacterial Vaginosis and Candida Vaginitis
Vaginitis is a common reason for clinical visits, with bacterial vaginosis and Candida vaginitis among the leading causes. Overlapping symptoms and reliance on microscopy, pH testing, and clinical observation... Read moreHematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read more
Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
Drug-resistant Neisseria gonorrhoeae is straining current treatment protocols and elevating the risk of complications across sexual health services. More than 500,000 cases are reported each year in the... Read morePathology
view channel
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreIndustry
view channelLumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio
LumiQuick Diagnostics, Inc. (Santa Clara, CA, USA) has announced the addition of the AOXRE product line to its portfolio and introduced expanded services to help biotechnology and diagnostic companies... Read more
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more








